A supramolecular assembly strategy for hydrophilic drug delivery towards synergistic cancer treatment
Source abstract
Abstract
To improve the drug loading, tumor targeting, and delivery simplicity of hydrophilic drugs, we propose a supramolecular assembly strategy that potentially benefits a wide range of hydrophilic drug delivery. Firstly, we choose a hydrophilic drug (tirapazamine) as a model drug to directly co-assemble with chlorin e6 (Ce6) at different molar ratios, and systematically evaluate the resultant Ce6-tirapazamine nanoparticles (CT NPs) in aspects of size distribution, polydispersity, morphology, optical properties and molecular dynamics simulation. Based on the assembling facts between Ce6 and tirapazamine, we summarize a plausible rule of the supramolecular assembly for hydrophilic drugs. To validate our findings, more drugs with increasing hydrophilicity, such as temozolomide, gemcitabine hydrochloride and 5-azacytidine, successfully co-assemble with Ce6 into nanostructures by following similar assembling behaviors, demonstrating that our assembling rule may guide a wide range of hydrophilic drug delivery. Next, the combination of Ce6 and tirapazamine was chosen as the representative to investigate the anti-tumor activities of the supramolecular assemblies. CT NPs showed synergistic anti-tumor efficacy, increased tumor accumulation and significant tumor progression and metastasis inhibition in tumor-bearing mice. We anticipate that the supramolecular assembly mechanism will provide broad guidance for developing easy-to-make but functional nanomedicines. STATEMENT OF SIGNIFICANCE: Although thousands of nanomedicines have been developed, only a few have been approved for clinical use. The manufacturing complexity significantly hinders the "bench-to-bed" translation of nanomedicines. Hence, we need to rethink how to conduct research on translational nanomedicines by avoiding more and more complex chemistry and complicated nanostructures. Here, we summarize a plausible rule according to multiple supramolecular assembly pairs and propose a supramolecular assembly strategy that can improve the drug loading, tumor targeting, and manufacturing simplicity of nanomedicine for hydrophilic drugs. The supramolecular assembly strategy would guide a broader range of drug delivery to provide a new paradigm for developing easy-to-make but multifunctional nanoformulations for synergistic cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Supramolecular Self-Assembly in Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
2. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy10.1002/adma.202203958 ↗
3. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics10.7150/thno.38069 ↗
4. Stimuli-responsive crosslinked nanomedicine for cancer treatment10.1002/EXP.20210134 ↗
5. Novel redox-responsive polymeric magnetosomes with tunable magnetic resonance property for in vivo drug release visualization and dual-modal cancer therapy10.1002/adfm.201802159 ↗
6. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
7. Two-way magnetic resonance tuning and enhanced subtraction imaging for non-invasive and quantitative biological imaging10.1038/s41565-020-0678-5 ↗
8. Brain co-delivery of first-line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy
9. A biomimetic nanomedicine targets orthotopic glioblastoma by combinatorial co-delivery of temozolomide and a methylguanine-DNA methyltransferase inhibitor
10. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
11. Indocyanine green potentiated paclitaxel nanoprodrugs for imaging and chemotherapy10.1002/EXP.20220008 ↗
12. Rational design of nanoparticles with deep tumor penetration for effective treatment of tumor metastasis10.1002/adfm.201801840 ↗
13. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond10.1016/j.jconrel.2012.04.038 ↗
14. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
15. The entry of nanoparticles into solid tumours10.1038/s41563-019-0566-2 ↗
16. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy10.1016/j.biomaterials.2013.07.037 ↗
17. Liposome composition in drug delivery design, synthesis, characterization, and clinical application10.1016/j.addr.2021.113851 ↗
18. Recent advancements in liposome technology10.1016/j.addr.2020.06.022 ↗
19. Recent advances on small-molecule nanomedicines for cancer treatment10.1002/wnan.1607 ↗
20. Tailor-made dual ph-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery10.1021/ja207150n ↗
21. Carrier-free, chemophotodynamic dual nanodrugs via self-assembly for synergistic antitumor therapy10.1021/acsami.6b02416 ↗
22. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy10.1021/ja505212y ↗
23. Self-assembled nanoparticle-mediated chemophototherapy reverses the drug resistance of bladder cancers through dual AKT/ERK inhibition
24. Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment10.1038/s41467-018-06093-5 ↗
25. Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy10.1016/j.biomaterials.2018.01.044 ↗
26. Co-delivery of Bee Venom melittin and a photosensitizer with an organic-inorganic hybrid nanocarrier for photodynamic therapy and immunotherapy10.1021/acsnano.9b04181 ↗
27. Spatiotemporal drug release visualized through a drug delivery system with tunable aggregation-induced emission10.1002/adma.201302365 ↗
28. Porphyrin-based nanomedicines for cancer treatment10.1021/acs.bioconjchem.9b00231 ↗
29. Quantitative self-assembly prediction yields targeted nanomedicines10.1038/s41563-017-0007-z ↗
30. Computationally guided high-throughput design of self-assembling drug nanoparticles10.1038/s41565-021-00870-y ↗
31. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles10.1016/j.biomaterials.2011.05.007 ↗
32. PEG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted, NIR light induced, photodynamic therapy10.1016/j.biomaterials.2013.08.041 ↗
33. Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer10.1002/anie.201103557 ↗
34. Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations10.1002/adma.201900927 ↗
35. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer10.1021/acsnano.7b00715 ↗
36. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
37. Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses10.2147/IJN.S203383 ↗
38. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma10.1023/A:1008249232000 ↗
39. Tirapazamine: A hypoxia-activated topoisomerase II poison
40. Selectively potentiating hypoxia levels by combretastatin A4 nanomedicine: toward highly enhanced hypoxia-activated prodrug tirapazamine therapy for metastatic tumors10.1002/adma.201805955 ↗
41. Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment10.1016/j.biomaterials.2021.121332 ↗
42. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗